Shandong Xinhua Pharmaceutical Company Limited (000756.SZ) announced that it has received the "Drug Supplement Approval Notice" for its Adrenaline Hydrochloride Injection from the National Medical Products Administration, indicating the product has passed the consistency evaluation for generic drug quality and efficacy.
The injection is primarily used to treat severe dyspnea caused by bronchospasm, rapidly alleviate anaphylactic shock induced by medications, and prolong the duration of local anesthesia. It also serves as a critical resuscitation medication for cardiac arrest due to various causes.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments